Immuncor Hits Milestone in GSK Collaboration
Source: Isis Innovation
Immunocore Limited, the Oxford based biotechnology company developing novel biological drugs to treat cancer and viral disease has announced the achievement of its first milestone in its research and licensing agreement with GlaxoSmithKline.
The achievement comes less than four months after the companies signed their agreement.
Founded in 2008, Immunocore Ltd is a privately owned biotechnology company developing a technology that generates novel drugs for the treatment of cancer and viral infection.
Immunocore traces its roots to Avidex Ltd, founded in 1999 as a spin-out from Isis Innovation Ltd at the University of Oxford to develop novel T Cell Receptor technology invented by the founder and chief scientist, Dr Bent Jakobsen.
Immunocore has major discovery collaborations ongoing with Genentech and GlaxoSmithKline.
The company was recently listed in the top 15 private biotech firms globally for 2013 by Fierce Biotech and named Best Biotech Dealmaker of 2013 at the OBN Awards.
Click here for full press release.